Liu, Xuewen
Wang, Fang
Xu, Chunwei
Chen, Xinru
Hou, Xue
Li, Qian http://orcid.org/0000-0001-9413-1877
Li, Pansong
Xie, Zhi
Liu, Yongdong
Chang, Lianpeng
Guan, Yanfang
Zhang, Xuchao
Yang, Ling
Wang, Hui
Yi, Xin
Zhang, Jianjun
Xia, Xuefeng
Moran, Cesar http://orcid.org/0000-0003-1158-5713
Chen, Likun http://orcid.org/0000-0002-7158-3878
Article History
Received: 23 July 2020
Revised: 8 November 2020
Accepted: 17 November 2020
First Online: 3 December 2020
Compliance with ethical standards
:
: The authors declare the following conflict of interest: QL, PL, L Chang, YG, and XX are current employees of Geneplus-Beijing. XY and LY hold leadership positions and stocks of Geneplus-Beijing. JZ reports grants from Merck, Johnson and Johnson, consultant fees, advisory fees or honoraria from Bristol Myers Squibb, AstraZeneca, Geneplus, Innovent, OrigMed, Roche outside the submitted work. The remaining authors declare no conflict of interest.
: The present study was reviewed and approved by the Research Ethics Committee of the Sun Yat-sen University Cancer Center (B2020-139-01).